IN THE ABSTRACT:

Please delete the abstract as originally filed which appears on the cover sheet of the Published Application. Add new abstract as enclosed herewith on a separate sheet.

REMARKS

Claims 3, 6 and 8-11 were amended to correct multiple dependency. Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned **"VERSION WITH MARKINGS TO SHOW CHANGES MADE"**.

Respectfully submitted,

YOUNG & THOMPSON

By _____

Benoît Castel
Attorney for Applicant
Customer No. 000466
Registration No. 35,041
745 South 23rd Street
Arlington, VA 22202
703/521-2297

December 13, 2001

"VERSION WITH MARKINGS TO SHOW CHANGES MADE"

Claims 3, 6 and 8-11 have been amended as follows:

3. (Amended) Compositions as claimed in claim 1 ~~or 2~~, wherein 5-aminosalicylic acid is inglobated in the molten lipophilic matrix by kneading, extrusion and/or granulation.

6. (Amended) Compositions as claimed in ~~any one of the above claims,~~ claim 1, comprising a gastro-resistant outer coating.

8. (Amended) Compositions as claimed in ~~any one of the above claims,~~ claim 1, in the form of tablets, capsules, minitablets, wherein the active ingredient is completely contained inside the lipophilic matrix.

9. (Amended) Compositions as claimed in ~~any one of claims 1 to 7,~~ claim 1, in the form of tablets, capsules, minitablets, wherein the active ingredient is dispersed both in the hydrophilic matrix and the lipophilic matrix.

10. (Amended) Compositions as claimed in ~~any one of the above claims,~~ claim 1, wherein the percentage of the active ingredient on the total composition weight ranges from 80 to 95%.

11. (Amended) A process for the preparation of the compositions of ~~claims 1-10,~~ claim 1, which comprises:

a) melt granulation of at least one portion of the active ingredient with the lipophilic excipients with melting point lower than 90°C;

b) mixing the granules from step a) with the hydrophilic excipients and subsequent tabletting or compression.